A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Clinical trial NCT00679211 · COMPLETED

Trial details

NCT number: NCT00679211
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2008-08-01
Primary completion: 2009-09-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.